Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors
Pathology and Oncology Research · 2023
DOI: 10.3389/pore.2023.1611070 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pathology and Oncology Research, 2023. Verfasst von Jingjing Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, B-Cell, Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Waldenström macroglobulinemia (WM) is a rare subtype of B-cell lymphoma. Rituximab-based combination therapy and Bruton’s tyrosine kinase ( BTK ) inhibitors have greatly improved the prognosis of WM. Despite the high response rate and good tolerance of BTK inhibitors in treatment of WM, a proportion of patients still experience disease progression. Case presentation: We report a 55-year-old man with relapsed WM. The patient achieved partial remission after six courses of CHOP chemotherapy and multiple plasma exchanges in initial treatment. He was admitted to the hospital with abdominal distension, and was diagnosed with relapsed WM and subsequently started on zanubrutinib. Disease progression and histological transformation occurred during treatment. We performed liquid biopsies on transformed plasma, tumor tissue and ascites at the same time and found high consistency between ascites and tissues. Moreover, we detected resistance mutations of BTK inhibitors ( BTK , PLCG2 ) in ascites that were not detected in plasma or tissue. Eventually, the patient died during the 15-month follow-up after relapse.
Conclusion
We describe a rare case of WM transformation to DLCBCL treated with chemoimmunotherapy and BTK inhibition. We analyzed tumor DNA obtained at different anatomic sites and circulating tumor DNA (ctDNA) derived from plasma and ascites specimens, with apparent significant temporal and spatial heterogeneity. The case specifically highlights the clinical value of ctDNA of ascites supernatant from WM patients, which is a more convenient and relatively noninvasive method compared with traditional invasive tissue biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Zitieren
APA
Zhu, J., Zhu, X., Xie, F., Ding, Y., Lu, H., Dong, Y., Li, P., Fu, J., Liang, A., Zeng, Y., & Xiu, B. (2023). Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors. Pathology and Oncology Research. https://doi.org/10.3389/pore.2023.1611070
Vancouver
Zhu J, Zhu X, Xie F, Ding Y, Lu H, Dong Y, et al. Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors. Pathology and Oncology Research. 2023. doi:10.3389/pore.2023.1611070
BibTeX
@article{Zhu2023,
author = {Zhu, Jingjing and Zhu, Xinyu and Xie, Fengyang and Ding, Yi and Lu, Huina and Dong, Yan and Li, Ping and Fu, Jianfei and Liang, Aibin and Zeng, Yu and Xiu, Bing},
title = {Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors},
journal = {Pathology and Oncology Research},
year = {2023},
doi = {10.3389/pore.2023.1611070}
}
EUVIMED